Contents

Commentaries
s1 Heated tobacco products: the example of IQOS S A Glantz
s7 Heated tobacco products: things we do and do not know I Stepanov, A Woodward

Research papers
s9 PMI’s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes S A Glantz
s13 Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke P Nakhovitsevich, J Liu, C M Havel, S Ibrahim, R Derakhshandeh, P Jakob III, M L Springer
s20 Assessment of industry data on pulmonary and immunosuppressive effects of IQOS F Motazed, L Chun, M A Manthey, C S Calfee, Jotts
s30 IQOS: examination of Philip Morris International’s claim of reduced exposure G St Helen, P Jakob III, N Nardone, N L Benowitz
s41 Heated tobacco products likely appeal to adolescents and young adults K McKelvey, I Popova, M Kim, B W Chatfee, M Vijayanathamavan, P Ling, B Halpern-Felsher
s48 IQOS labelling will mislead consumers K McKelvey, I Popova, M Kim, I K Lempert, B W Chatfee, M Vijayanathamavan, P Ling, B Halpern-Felsher
s55 Awareness and use of heated tobacco products among US adults, 2016–2017 A L Nyman, S R Weaver, I Popova, T F Pechacek, J Huang, D L Ashley, M P Erikson
s62 Impact of modified risk tobacco product claims on beliefs of US adults and adolescents S El-Toukhy, S A Baig, M Jeong, M J Byron, K M Rabin, N T Brewer
s70 Examining perceptions about IQOS heated tobacco product: consumer studies in Japan and Switzerland E C Hair, M Bennett, E Sheen, J Connell, J Briggs, Z Fen, J G Wilten, D Vallone

November 2018 Volume 27 Issue S1

s82 Modelling the impact of a new tobacco product: review of Philip Morris International’s Population Health Impact Model as applied to the IQOS heated tobacco product W B Max, H-Y Sung, J Lightwood, Y Wang, Y Tao
s87 Light and mild redux: heated tobacco products’ reduced exposure claims are likely to be misunderstood as reduced risk claims I Popova, I K Lempert, S A Glantz
s96 Invisible smoke: third-party endorsement and the resurrection of heat-not-burn tobacco products J Elias, P M Ling
s102 Revolution or redux? Assessing IQOS through a precursor product J Elias, I M Dutra, G St. Helen, P M Ling

Brief reports
s26 Cytotoxic effects of heated tobacco products (HTP) on human bronchial epithelial cells N J Leigh, P L Tran, R J O’Connor, M I Gontiewicz
s74 Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults J Kim, H Yu, S Lee, Y-J Pick

Research letters
s37 Tobacco-specific nitrosamines (TSNA) in heated tobacco product IQOS N J Leigh, M N Palumbo, A M Marino, R J O’Connor, M I Gontiewicz
s39 Possible hepatotoxicity of IQOS L Chun, F Motazed, M Manthey, C Calfee, J Jotts

Industry watch
s78 IQOS campaign in Israel J J Rosen, S Kislev

Special communication
s111 Heated tobacco products: another tobacco industry global strategy to slow progress in tobacco control S A Bialous, S A Glantz
s118 Heated tobacco product regulation under US law and the FCTC I K Lempert, S A Glantz